’Omics’ in Chronic Liver Disease

Nov 10 2025
Convention Center: Room 146A, Level 1
11:00 AM - 12:30 PM

World Class Speakers

Renumathy Dhanasekaran, MD, PhD
Abstract Presenter

Renumathy Dhanasekaran, MD, PhD

Stanford University
Neehar D. Parikh, MD, MS, FAASLD
Abstract Presenter

Neehar D. Parikh, MD, MS, FAASLD

University of Michigan Medical Center
Stephanie Rutledge, MD, MB BCh, BAO, MRCPI
Abstract Presenter

Stephanie Rutledge, MD, MB BCh, BAO, MRCPI

Weill Cornell Medicine
Neehar D. Parikh, MD, MS, FAASLD
Moderator

Neehar D. Parikh, MD, MS, FAASLD

University of Michigan Medical Center
Stephanie Rutledge, MD, MB BCh, BAO, MRCPI
Moderator

Stephanie Rutledge, MD, MB BCh, BAO, MRCPI

Weill Cornell Medicine

Description

The 'omics' revolution offers a gateway to a new level of precision medicine in chronic liver disease.  In this session, we highlight  six outstanding examples of genomic and metabolic explorations into the pathogenesis and diagnosis of HCC and MASLD.

Journey Maps

Presentations

11:00 AM - 11:15 AM
Aug 06 2026
Convention Center - Room 146A, Level 1

Integration Across Primary Liver Tumors Identifies Clinically Relevant Molecular Subtypes of HCC

Renumathy Dhanasekaran, MD, PhD , Abstract Presenter
Basic Science
Liver Cancer
MASLD
11:15 AM - 11:30 AM
Aug 06 2026
Convention Center - Room 146A, Level 1

Per- and Polyfluoroalkyl Substances, Genetic Susceptibility, and Hepatocellular Carcinoma: A Nested Case Control Study in the Multiethnic Cohort

Neehar D. Parikh, MD, MS, FAASLD , Abstract Presenter
Basic Science
Liver Cancer
MASLD
12:00 PM - 12:15 PM
Aug 06 2026
Convention Center - Room 146A, Level 1

Genome-wide CRISPR screen identifies loss of function of DNAJC22 protects against steatotic liver disease

Stephanie Rutledge, MD, MB BCh, BAO, MRCPI , Abstract Presenter
Basic Science
Liver Cancer
MASLD
12:15 PM - 12:30 PM
Aug 06 2026
Convention Center - Room 146A, Level 1

An Epigenetic Atlas of MASH: Ultra-Deep Paired Liver Tissue and Plasma cfDNA Methylation Sequencing Enables Non-Invasive Measurement of Pathway Activity

Neehar D. Parikh, MD, MS, FAASLD , Abstract Presenter
Basic Science
Liver Cancer
MASLD

Objectives

  • Discuss genomic advances impacting our understanding of the mechanisms of hepatocarinogenesis.
  • Identify novel targets for future therapeutic interventions in hepato-biliary cancers.
  • Recognize new metabolic pathways involved in MASLD.